$NMRD
Nemaura Medical Inc. Stock $nmrd

$nmrd Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000107997324000215 Filed on February 12, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2022 Q4
Revenue			$3.017K
YoY Change			-98.36%
Cost Of Revenue			$2.971K
YoY Change			-98.28%
Gross Profit			$46.00
YoY Change			-99.59%
Gross Profit Margin			1.52%
Selling, General & Admin		$1.250M	$239.6K
YoY Change		421.7%	-82.78%
% of Gross Profit			520934.78%
Research & Development		$291.1K	$393.7K
YoY Change		-26.07%	-4.51%
% of Gross Profit			855971.74%
Depreciation & Amortization		$79.68K	$95.92K
YoY Change		-16.93%	65.21%
% of Gross Profit			208521.74%
Operating Expenses		$1.541M	$633.4K
YoY Change		143.34%	-64.88%
Operating Profit		-$1.541M	-$633.3K
YoY Change		143.36%	-64.67%
Interest Expense		-$1.623M	-$1.083M
YoY Change		49.89%	-33.93%
% of Operating Profit
Other Income/Expense, Net		$1.003M	$273.00
YoY Change		367299.27%	-93.77%
Pretax Income		-$2.161M	-$1.716M
YoY Change		25.94%	-49.99%
Income Tax
% Of Pretax Income
Net Earnings		-$2.161M	-$1.716M
YoY Change		25.94%	-49.99%
Net Earnings / Revenue			-56886.91%
Basic Earnings Per Share		-$0.07	-$0.07
Diluted Earnings Per Share		-$0.07	-$0.07
COMMON SHARES
Basic Shares Outstanding	28.90M shares	28.90M shares	24.10M shares
Diluted Shares Outstanding		28.90M shares	24.10M shares

Balance Sheet

Concept	2023 Q4	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$137.4K	$7.341M
YoY Change	-98.13%	-68.15%
Cash & Equivalents	$137.4K	$7.341M
Short-Term Investments
Other Short-Term Assets	$315.6K	$1.217M
YoY Change	-74.07%	157.69%
Inventory	$3.672M	$2.352M
Prepaid Expenses
Receivables		$25.32K
Other Receivables		$0.00
Total Short-Term Assets	$4.372M	$10.94M
YoY Change	-60.02%	-56.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$558.7K	$581.9K
YoY Change	-3.99%	28.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$2.026M
YoY Change
Total Long-Term Assets	$796.7K	$2.026M
YoY Change	-60.67%	0.37%
TOTAL ASSETS
Total Short-Term Assets	$4.372M	$10.94M
Total Long-Term Assets	$796.7K	$2.026M
Total Assets	$5.169M	$12.96M
YoY Change	-60.12%	-52.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$352.5K	$171.2K
YoY Change	105.88%	-3.06%
Accrued Expenses	$281.1K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$19.64M	$11.51M
YoY Change	70.62%	-22.48%
Total Short-Term Liabilities	$23.00M	$13.22M
YoY Change	73.94%	-18.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$8.558M
YoY Change	-100.0%	-1.78%
Other Long-Term Liabilities	$0.00	$1.043M
YoY Change	-100.0%	-13.23%
Total Long-Term Liabilities	$0.00	$9.600M
YoY Change	-100.0%	-3.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.00M	$13.22M
Total Long-Term Liabilities	$0.00	$9.600M
Total Liabilities	$23.00M	$22.82M
YoY Change	0.77%	-12.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$57.84M	-$47.19M
YoY Change	22.57%
Common Stock	$41.02M	$38.32M
YoY Change	7.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$17.83M	-$9.859M
YoY Change
Total Liabilities & Shareholders Equity	$5.169M	$12.96M
YoY Change	-60.12%	-52.12%

Cashflow Statement

Concept	2023 Q4	2022 Q4
OPERATING ACTIVITIES
Net Income	-$2.161M	-$1.716M
YoY Change	25.94%	-49.99%
Depreciation, Depletion And Amortization	$79.68K	$95.92K
YoY Change	-16.93%	65.21%
Cash From Operating Activities	-$1.484M	-$1.541M
YoY Change	-3.73%	75.64%
INVESTING ACTIVITIES
Capital Expenditures	$6.810K	$57.64K
YoY Change	-88.19%	-129.75%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$6.810K	-$57.64K
YoY Change	-88.19%	-70.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.998M	-1.700M
YoY Change	76.41%	-34.27%
NET CHANGE
Cash From Operating Activities	-1.484M	-1.541M
Cash From Investing Activities	-6.810K	-57.64K
Cash From Financing Activities	-2.998M	-1.700M
Net Change In Cash	-4.489M	-3.298M
YoY Change	36.09%	-9.8%
FREE CASH FLOW
Cash From Operating Activities	-$1.484M	-$1.541M
Capital Expenditures	$6.810K	$57.64K
Free Cash Flow	-$1.490M	-$1.599M
YoY Change	-6.77%	133.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001602078
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2023Q4	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Revenues Revenues		usd
	us-gaap	Revenues Revenues		usd
CY2023Q4	us-gaap	Cost Of Revenue CostOfRevenue		usd
	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2023Q4	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
CY2022Q4	nmrd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
	nmrd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
	us-gaap	Inventory Write Down InventoryWriteDown		usd
	us-gaap	Paid In Kind Interest PaidInKindInterest		usd
	nmrd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts		usd
	nmrd	Debt Discount Recognized Upon Issuance Of Notes Payable DebtDiscountRecognizedUponIssuanceOfNotesPayable		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38355
	dei	Entity Registrant Name EntityRegistrantName	Nemaura Medical Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5027260
	dei	Entity Address Address Line1 EntityAddressAddressLine1	57 West 57th Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Manhattan
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
	dei	City Area Code CityAreaCode	646
	dei	Local Phone Number LocalPhoneNumber	416-8000
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28899402	shares
CY2023Q4	us-gaap	Cash Cash	137416	usd
CY2023Q1	us-gaap	Cash Cash	10105135	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	3671533	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1754852	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	169174	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	357934	usd
CY2023Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	247788	usd
CY2023Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	409648	usd
CY2023Q4	nmrd	Deposit On Foreign Exchange Contract DepositOnForeignExchangeContract	146434	usd
CY2023Q1	nmrd	Deposit On Foreign Exchange Contract DepositOnForeignExchangeContract	909666	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4372345	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	13537235	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	558697	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	641906	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	238033	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	384092	usd
CY2023Q4	us-gaap	Assets Assets	5169075	usd
CY2023Q1	us-gaap	Assets Assets	14563233	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	352483	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	326641	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	281055	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	130678	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	19643038	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	16942500	usd
CY2023Q4	nmrd	Payable To Related Parties PayableToRelatedParties	800403	usd
CY2023Q1	nmrd	Payable To Related Parties PayableToRelatedParties	920780	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1184412	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	123640	usd
CY2023Q4	nmrd	Foreign Exchange Contract Derivative Liability ForeignExchangeContractDerivativeLiability	242295	usd
CY2023Q1	nmrd	Foreign Exchange Contract Derivative Liability ForeignExchangeContractDerivativeLiability	731730	usd
CY2023Q4	nmrd	Warrant Liability WarrantLiability	492000	usd
CY2023Q1	nmrd	Warrant Liability WarrantLiability	3092000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22995686	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	22267969	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	3087651	usd
CY2023Q1	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	1021811	usd
CY2023Q4	us-gaap	Liabilities Liabilities	22995686	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1716278	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5968086	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9460888	usd
CY2023Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	204828	usd
CY2022Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-556080	usd
	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-44327	usd
	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-864328	usd
CY2023Q1	us-gaap	Liabilities Liabilities	26377431	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	42000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	42000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28899402	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28899402	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28899402	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28899402	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	28899	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	28899	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	40991377	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	40991377	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57843297	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51875211	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1003590	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-959263	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-17826611	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-11814198	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5169075	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14563233	usd
CY2022Q4	us-gaap	Revenues Revenues	3017	usd
	us-gaap	Revenues Revenues	77044	usd
CY2022Q4	us-gaap	Cost Of Revenue CostOfRevenue	2971	usd
	us-gaap	Cost Of Revenue CostOfRevenue	75327	usd
CY2022Q4	us-gaap	Gross Profit GrossProfit	46	usd
	us-gaap	Gross Profit GrossProfit	1717	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	291104	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	393747	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1332664	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	980862	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1250149	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1230160	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4317358	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1509095	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	1541253	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	1623907	usd
	us-gaap	Operating Expenses OperatingExpenses	5650022	usd
	us-gaap	Operating Expenses OperatingExpenses	2489957	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1541253	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1623907	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5650022	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2488240	usd
CY2023Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1925678	usd
CY2022Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1082949	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-3407499	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4152437	usd
CY2023Q4	nmrd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	1003000	usd
	nmrd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	2600000	usd
CY2023Q4	nmrd	Change In Fair Value Of Foreign Exchange Contract Derivative Liability ChangeInFairValueOfForeignExchangeContractDerivativeLiability	302453	usd
CY2022Q4	nmrd	Change In Fair Value Of Foreign Exchange Contract Derivative Liability ChangeInFairValueOfForeignExchangeContractDerivativeLiability	990532	usd
	nmrd	Change In Fair Value Of Foreign Exchange Contract Derivative Liability ChangeInFairValueOfForeignExchangeContractDerivativeLiability	489435	usd
	nmrd	Change In Fair Value Of Foreign Exchange Contract Derivative Liability ChangeInFairValueOfForeignExchangeContractDerivativeLiability	-2820211	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-2161478	usd
CY2023Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1956650	usd
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4831171	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6012413	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10325216	usd
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28899402	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28899402	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24103196	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24103196	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28899402	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28899402	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24103196	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24103196	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-15869961	usd
CY2023Q4	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	204828	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-2161478	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-17826611	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-11814198	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-44327	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5968086	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-17826611	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-8698934	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	423	usd
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	556080	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1716278	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9858709	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	466084	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	423	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-864328	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9460888	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9858709	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5968086	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9460888	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	309684	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	268595	usd
	us-gaap	Inventory Write Down InventoryWriteDown	104449	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1803126	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4152437	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	488022	usd
	nmrd	Change In Fair Value Of Foreign Exchange Contract Derivative Liability. ChangeInFairValueOfForeignExchangeContractDerivativeLiability.	-489435	usd
	nmrd	Change In Fair Value Of Foreign Exchange Contract Derivative Liability. ChangeInFairValueOfForeignExchangeContractDerivativeLiability.	635494	usd
	nmrd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	2600000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1113853	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	467070	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2021130	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	864636	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	25842	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	34897	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	120378	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-75977	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	150377	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10105135	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-167568	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-297419	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7203676	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6090181	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	135168	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	27879	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	76807	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	275758	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-76807	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-438805	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	696	usd
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	273	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	6500000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	4700000	usd
	nmrd	Principal Payments On Notes Payable PrincipalPaymentsOnNotesPayable	9178261	usd
	nmrd	Principal Payments On Notes Payable PrincipalPaymentsOnNotesPayable	7974282	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2678261	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3273859	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-9958745	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-9802845	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-8975	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-605548	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10105135	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17749233	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137416	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7340840	usd
	us-gaap	Interest Paid Net InterestPaidNet	921000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1522372	usd
	nmrd	Debt Discount Recognized Upon Issuance Of Notes Payable DebtDiscountRecognizedUponIssuanceOfNotesPayable	1310000	usd
	us-gaap	Profit Loss ProfitLoss	-5968086	usd
	nmrd	Net Cash Provided By Used In Operating Activities Continuing Operation NetCashProvidedByUsedInOperatingActivitiesContinuingOperation	7203676	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_z07Xm6QyoPJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span style="text-decoration: underline"><span id="xdx_867_zdlHcKwzIBQ9">Use of Estimates</span></span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant estimates include the assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity instruments, the fair value of derivative liabilities, valuation of stock options issued for services, and deferred tax valuation allowances. Actual results may differ from those estimates.<b> </b></p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137416	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3553811	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1586777	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	117722	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	168075	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	3671533	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1754852	usd
	nmrd	Additional Inventory Write Down AdditionalInventoryWriteDown	104000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5273551	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1613098	shares
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	usd
CY2023Q4	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	242295	usd
CY2023Q4	nmrd	Warrant Derivative Liability Fair Value WarrantDerivativeLiabilityFairValue	492000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	734295	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	usd
CY2023Q1	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	731730	usd
CY2023Q1	nmrd	Warrant Derivative Liability Fair Value WarrantDerivativeLiabilityFairValue	3092000	usd
CY2023Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3823730	usd
CY2023Q1	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	920782	usd
CY2022Q1	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	-101297	usd
	nmrd	Amounts Invoiced By Pharma To Ddl Nm And Tcl Primarily Relating To Research And Development Expenses AmountsInvoicedByPharmaToDdlNmAndTclPrimarilyRelatingToResearchAndDevelopmentExpenses	4211705	usd
	nmrd	Amounts Invoiced By Pharma To Ddl Nm And Tcl Primarily Relating To Research And Development Expenses AmountsInvoicedByPharmaToDdlNmAndTclPrimarilyRelatingToResearchAndDevelopmentExpenses	2833546	usd
	nmrd	Amounts Invoiced By Ddl To Pharma AmountsInvoicedByDdlToPharma	0	usd
	nmrd	Amounts Invoiced By Ddl To Pharma AmountsInvoicedByDdlToPharma	-3159	usd
	nmrd	Amounts Received From Pharma AmountsReceivedFromPharma	0	usd
	nmrd	Amounts Received From Pharma AmountsReceivedFromPharma	4452	usd
	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	4311770	usd
	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	2789939	usd
	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	-20314	usd
	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	31077	usd
CY2023Q4	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	800403	usd
CY2022Q4	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	-25320	usd
CY2023Q1	nmrd	Warrants Issued WarrantsIssued	4796206	shares
CY2023Q1	nmrd	Volatility Interest Rate VolatilityInterestRate	1	pure
CY2022Q3	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	6250000	usd
CY2022Q3	nmrd	Fair Value Of Contract Liability Leveraged Amounts FairValueOfContractLiabilityLeveragedAmounts	12500000	usd
	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	On each monthly settlement date, if the USD/GBP spot rate is above $1.359, the Company has the right to convert $250,000 USD into GBP at a fixed rate of $1.359. If the spot rate is between $1.359 and $1.319 on the settlement date, the Company has no obligations, but can convert $250,000 USD into GBP at the spot rate. Finally, if the spot rate is below $1.319 on the monthly settlement date, the Company is obligated to convert $500,000 USD (the settlement date leveraged amount) into GBP at the fixed rate of $1.359. Alternatively, instead of selling $500,000 USD, the Company can pay the difference in the spot rate and the $1.359 exchange rate for $500,000 USD (net settle) to the counterparty
CY2023Q4	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	2000000	usd
CY2023Q1	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	4250000	usd
CY2023Q4	nmrd	Fair Value Of Contract Liability Leveraged Amounts FairValueOfContractLiabilityLeveragedAmounts	4000000	usd
CY2023Q1	nmrd	Fair Value Of Contract Liability Leveraged Amounts FairValueOfContractLiabilityLeveragedAmounts	8500000	usd
	nmrd	Fair Value Of Contract Liabilities Expected Remaining Term FairValueOfContractLiabilitiesExpectedRemainingTerm	P8M
CY2023	nmrd	Fair Value Of Contract Liabilities Expected Remaining Term FairValueOfContractLiabilitiesExpectedRemainingTerm	P17M
CY2023Q4	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	242295	usd
CY2023Q1	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	731730	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	19916995	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20797234	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	273957	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	767083	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	19643038	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	20030151	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	19643038	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	16942500	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3087651	usd

Files In Submission

Name	View Source	Status
0001079973-24-000215-index-headers.html	Edgar Link	pending
0001079973-24-000215-index.html	Edgar Link	pending
0001079973-24-000215.txt	Edgar Link	pending
0001079973-24-000215-xbrl.zip	Edgar Link	pending
ex31x1.htm	Edgar Link	pending
ex31x2.htm	Edgar Link	pending
ex32x1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmrd-20231231.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nmrd-20231231_cal.xml	Edgar Link	unprocessable
nmrd-20231231_def.xml	Edgar Link	unprocessable
nmrd-20231231_lab.xml	Edgar Link	unprocessable
nmrd_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nmrd_10q_htm.xml	Edgar Link	completed
nmrd-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMRD
Nemaura Medical Inc. Stock $nmrd

2024 Q1 Form 10-Q Financial Statement

#000107997324000215 Filed on February 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMRD Nemaura Medical Inc. Stock $nmrd

2024 Q1 Form 10-Q Financial Statement

#000107997324000215 Filed on February 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMRD
Nemaura Medical Inc. Stock $nmrd